Cutler Group’s VistaGen Therapeutics VTGN Stock Holding History

Cutler Group’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-200	Closed	-$1K	–	3751
2023 Q4	$1K	Buy	+200	New	+$757	﹤0.01%	3496

Other funds holding VTGN

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Cutler Group's VTGN Position: Q1 2024 in Review

Cutler Group sold out of VistaGen Therapeutics (VTGN) in Q1 2024, closing a stake of 200 shares — an estimated $1K sold.

Cutler Group first reported a position in VTGN in Q4 2023 and held it in 1 quarter. The position peaked at $1K in Q4 2023. 42 funds tracked by Wall St. Rank hold VTGN as of Q1 2024.

Cutler Group reported no remaining VistaGen Therapeutics position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 200 VistaGen Therapeutics shares in Q1 2024, an estimated $1K.
Cutler Group first reported a position in VistaGen Therapeutics in Q4 2023 and held it in 1 quarter.
Cutler Group's VistaGen Therapeutics position peaked at $1K in Q4 2023.
42 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.